Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 4
2006 1
2007 5
2008 1
2009 10
2010 6
2011 3
2012 6
2013 9
2014 7
2015 5
2016 4
2017 9
2018 14
2019 19
2020 21
2021 28
2022 19
2023 13
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

176 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean ni wen chiu (7 results)?
The screening, diagnosis, and management of patients with autosomal dominant polycystic kidney disease: A national consensus statement from Taiwan.
Yen PW, Chen YA, Wang W, Mao FS, Chao CT, Chiang CK, Lin SH, Tarng DC, Chiu YW, Wu MJ, Chen YC, Kao JT, Wu MS, Lin CL, Huang JW, Hung KY. Yen PW, et al. Among authors: chiu yw. Nephrology (Carlton). 2024 May;29(5):245-258. doi: 10.1111/nep.14287. Epub 2024 Mar 10. Nephrology (Carlton). 2024. PMID: 38462235 Review.
Therapy as prevention toward HCV elimination in maintenance hemodialysis: a multi-center, prospective cohort study.
Huang CF, Dai CY, Wang CW, Liang PC, Wei YJ, Tsai PC, Jang TY, Hsu PY, Jia-Jung Lee, Niu SW, Huang JC, Yeh ML, Huang CI, Hsieh MY, Lin YH, Chen SC, Chiu YW, Huang JF, Chang JM, Hwang SJ, Chuang WL, Yu ML; FORMOSA-LIKE investigators. Huang CF, et al. Among authors: chiu yw. Clin Kidney J. 2023 Jun 14;16(12):2429-2436. doi: 10.1093/ckj/sfad138. eCollection 2023 Dec. Clin Kidney J. 2023. PMID: 38046041 Free PMC article.
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
176 results